Clinical Trials Logo

Clinical Trial Summary

The reirradiation of thoracic tumor is difficult. The possibility of surgery or re course radiotherapy is very small. In the NCCN guideline, only systemic treatment is recommended. However, the effective rate of systemic treatment is low. SBRT has the characteristics of high dose in tumor target area and low dose in surrounding normal tissues. In theory, SBRT is more conducive to the protection of normal tissues and can potentially be used in the salvage treatment of recurrent lesions after radiotherapy. Even so, SBRT is still controversial in the rescue treatment of recurrent lung cancer after radiotherapy, especially for "ultral-central" lesions close to mediastinal structures (such as bronchus, esophagus and large blood vessels), which have a high probability of fatal side effects. However, a few studies on the application of SBRT in the reirradiation for ultral-central lung cancer have shown acceptable safety and efficacy. Generally speaking, there are few studies on SBRT in the treatment of recurrent ultral-central tumor with limited data. The purpose of this study is to further evaluate the efficacy and toxicities of SBRT in the treatment of recurrent ultral-central tumors after radiotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05189054
Study type Observational
Source Peking University Third Hospital
Contact Zhe Ji, M.D.
Phone 008618710002823
Email aschoff@163.com
Status Recruiting
Phase
Start date May 1, 2022
Completion date April 30, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05045040 - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions N/A
Recruiting NCT05415475 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT04596865 - Recurrence After Whipple's (RAW) Study
Recruiting NCT06103617 - Safety and Superiority of Penicillamine in Radiosensitization of Recurrent Head and Neck Cancer Phase 2
Completed NCT05364905 - Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial Carcinoma
Recruiting NCT05396300 - A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors Phase 1
Completed NCT03441100 - TCR-engineered T Cells in Solid Tumors: IMA202-101 Phase 1
Recruiting NCT05359445 - IMA401 TCER® in Recurrent and/or Refractory Solid Tumors Phase 1
Recruiting NCT03686124 - ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors Phase 1
Not yet recruiting NCT04889742 - Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors Phase 2
Completed NCT03132038 - Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck Phase 2
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Not yet recruiting NCT02410187 - SBRT for Extra-cranial Oligorecurrent Tumor Phase 2
Not yet recruiting NCT04784221 - Nanoparticles and Hypofractionated Protontherapy for Reirradiation of Pantumor Relapse Phase 2
Recruiting NCT05855811 - PREventing Second Cancers With DOSTARlimab Phase 2
Recruiting NCT05626829 - Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma Phase 2
Completed NCT03941262 - Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy Phase 1
Recruiting NCT06372574 - A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors Phase 1
Completed NCT05200195 - Deep Learning Model for the Prediction of Post-LT HCC Recurrence
Completed NCT03760952 - Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling